Intel Corp (NASDAQ:INTC, XETRA:INL) stock dropped more than 6% after Thursday’s closing bell as the technology firm’s first quarter guidance fell short of Wall Street estimates.
For Q1, Intel guided revenue in the range of $11.7 billion to $12.7 billion, at the midpoint below the consensus $12.63 billion.
Mobileye (NASDAQ:MBLY) shares fell more than 3% after the autonomous driving technology company reported fourth quarter results that missed Wall Street expectations on earnings, even as revenue came in above forecasts.
The company reported adjusted earnings per share of $0.06 for the fourth quarter of 2025, well below the $0.24 analysts had expected.
Alibaba Group (NYSE:BABA) is reportedly preparing an initial public offering for its chipmaking arm, T-Head Semiconductor.
According to a report from Bloomberg, which cited people familiar with the matter, Alibaba plans to first restructure T-Head into a standalone business with partial ownership held by employees, before exploring a potential initial public offering.
Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization LifeArc, reducing future royalties tied to the experimental drug Teverelix, a move the company said improves the asset’s long-term commercial profile.
Under the revised agreement, royalties payable on worldwide net sales of Teverelix have been cut to 2% from about 4%, with the royalty term clarified on a country-by-country basis, Medicus said.
GE Aerospace (NYSE:GE) posted fourth quarter earnings that topped both profit and revenue estimates, but its shares came under pressure as investors weighed signs of slowing growth and a 2026 outlook that points to more moderate expansion than previously expected.
For Q4, GE Aerospace posted adjusted earnings per share of $1.57, topping the consensus estimate of $1.43 by $0.14.
Procter & Gamble Co (NYSE:PG, XETRA:PRG) on Thursday reported flat organic sales for its fiscal second quarter, missing market expectations, as price increases were offset by lower volumes while higher restructuring charges weighed on year-on-year earnings growth.
The consumer goods maker said organic sales were unchanged in the quarter, compared with analyst expectations for modest growth. Net sales rose 1% from a year earlier to $22.2 billion, while core earnings per share came in at $1.88, slightly above expectations and flat from a year earlier.
Shares in video games maker Ubisoft Entertainment (OTC:UBSFF, EPA:UBI) tanked 34% to a decade's low after the Assassin's Creed cancelled six games as part of a restructuring, including a much-anticipated 'Prince of Persia' remake.
The Paris-based computer games designer is dividing itself into five 'creative houses', it said in a statement on Wednesday night, with the aim of clamping down on costs and becoming a "more gamer-centric organization... with faster, decentralized decision-making and a greater ability to quickly adapt to players’ expectations".
Shares in Cloudbreak Discovery PLC (LSE:CDL, OTC:CDBDF) fell 18% to 0.62p despite reporting high-grade gold assay results from its Crofton project in Western Australia, as investors reacted to dilution from a £1.85 million placing announced alongside the update.
The stock has powered up 373% over the past 12 months.
Shares in MedPal AI climbed 8% to 5.75p after the company announced a major leap in operational efficiency at its pharmacy subsidiary, MedPal Limited.
The AIM-listed digital health firm said recent server infrastructure upgrades had delivered a 30-fold increase in prescription dispensing speed. The Robopharma robot, which previously processed 40 prescriptions an hour, can now handle more than 100 in under five minutes.